The litigation, filed by Bleichmar Fonti & Auld LLP, centers on allegations that Embecta executives misled shareholders regarding the competitive health of its insulin pen needle division. While the company publicly described its product portfolio as resilient and trending positively, the complaint asserts that management ignored mounting market softness and significant share loss to competitors.
The discrepancy between public statements and internal performance became clear on May 5, 2026, when Embecta reported second-quarter results that missed guidance. The company cited a decline in retail volume and loss of business from a key customer, subsequently slashing its quarterly dividend from $0.15 to $0.01 per share. This disclosure wiped more than half the company's market value in one session, with the stock price falling from $9.25 to $3.90. The case, captioned Apitz-Grossman v. Embecta Corp., et al., alleges violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.
Comments (0)
No comments yet. Be the first!